Drug Development Pharma - August 12, 2014
Kancera gets additional funding
Research company Kancera has received a final grant to one of the company’s cancer projects. The grant is given by the Swedish innovation authority Vinnova which has identified Kancera as a young innovative company with growth potential. The company develops new treatment methods for cancer and their ROR project has been allocated another SEK 500 […]
Drug Development Pharma - August 6, 2014
Boehringer Ingelheim returns project to Orexo
Orexo has announced that Boehringer Ingelheim has decided to return the OX-MPI project to Orexo. The project aims to develop products based on specific inhibition of prostaglandin E2 (PGE2) in different disease conditions. Since 2005, Boehringer Ingelheim has been responsible for all research and development within the project. Orexo will evaluate the results from Boehringer Ingelheim. When […]
Drug Development Pharma - August 5, 2014
EMA looks to stimulate better use of genomic data in medicines development
The agency is taking a look at better use of genomic data and biomarkers in medicines development and safety monitoring. The European Medicines Agency has released a draft concept paper for public consultation outlining the key elements that will be developed in a guideline on good genomics biomarker practices. The concept paper proposes a framework for the generation […]
Drug Development Pharma - August 4, 2014
Medivir licenses respiratory syncytial virus drug program
The company has entered a license agreement with Boehringer Ingelheim International GmbH for exclusive, global rights to a drug program for the treatment and prevention of RSV infection. The program includes novel compounds that inhibit the RSV fusion protein, which is a key mediator of viral entry into host cells and a target for new […]
Drug Development Pharma - July 2, 2014
Pelago Bioscience enters agreement with GSK
Pelago Bioscience AB has entered a method licensing agreement with GlaxoSmithKline. The agreement regards the use of the Cellular Thermal Shift Assay for determination and quantification of drug–target interactions. Under the agreement, Pelago Bioscience grants GSK a license to the CETSA method for use in research & development. Pelago Bioscience was spun out from the […]
Drug Development Pharma - June 25, 2014
Sobi files for EU approval of Xiapex for Peyronies disease
Sobi has filed for an extension of the label for Xiapex with the European Medicines Agency (EMA) to include the indication of Peyronie’s disease. The filing is based on positive safety and efficacy outcome data from two double-blind placebo-controlled studies, IMPRESS I and II (The Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies) which […]
